GSK PLC GSK shares were unchanged Friday at £13.50, on what proved to be an all-around grim trading session for the stock ...

Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid ...

Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...

Find insight on Zydus Lifesciences, Biotech and more in the latest Market Talks covering the Health Care sector.

British drug maker GSK plc (GSK, GSK.L) announced Friday that the US Food and Drug Administration has accepted for review the ...

GSK announced on Friday that the US Food and Drug Administration (FDA) has accepted its regulatory application for a ...

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

In a bid to help the immune system of autoimmune disease patients reset, a San Francisco startup startup has raised $120 ...

Kotak Strategic Situations India Fund Il, managed by Kotak Alternate Asset Managers Ltd, has made an investment  Rs 940 crore ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...

The FDA has granted BTD to GSK’22, a B7-H3-targeted antibody-drug conjugate, for the treatment of adult patients with ...

Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...